JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $103,990,000 | +1.9% | 2,275,000 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $102,057,000 | +40.8% | 2,275,000 | -6.2% | 0.02% | +35.3% |
| Q2 2017 | $72,483,000 | +53.4% | 2,425,000 | +13.8% | 0.02% | +54.5% |
| Q1 2017 | $47,265,000 | +15.3% | 2,130,000 | -2.1% | 0.01% | +10.0% |
| Q4 2016 | $41,008,000 | -35.6% | 2,175,501 | +2.6% | 0.01% | -41.2% |
| Q3 2016 | $63,636,000 | -54.5% | 2,120,501 | -41.7% | 0.02% | -55.3% |
| Q2 2016 | $139,741,000 | +0.0% | 3,635,302 | -0.9% | 0.04% | -2.6% |
| Q1 2016 | $139,695,000 | -15.4% | 3,667,501 | -2.4% | 0.04% | -15.2% |
| Q4 2015 | $165,217,000 | +8.1% | 3,757,501 | 0.0% | 0.05% | +2.2% |
| Q3 2015 | $152,893,000 | -24.2% | 3,757,501 | -0.7% | 0.04% | -18.2% |
| Q2 2015 | $201,721,000 | +14.1% | 3,782,501 | +16.6% | 0.06% | +14.6% |
| Q1 2015 | $176,738,000 | +65.9% | 3,243,251 | +34.8% | 0.05% | +65.5% |
| Q4 2014 | $106,539,000 | – | 2,406,501 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |